We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-2.59%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.57B
AUM Growth
-$69.4M
Cap. Flow
+$212M
Cap. Flow %
5.95%
Top 10 Hldgs %
61.01%
Holding
66
New
4
Increased
9
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$70.7M
2
GPCR icon
Structure Therapeutics
GPCR
+$68.8M
3
CELC icon
Celcuity
CELC
+$58M
4
CGEM icon
Cullinan Oncology
CGEM
+$54.4M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$43M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$116M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$44.6M
3
KURA icon
Kura Oncology
KURA
+$14.5M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$12.8M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
26
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.79B
$38.9M 1.09%
1,569,422
-294,387
-16% -$8.35M
ANNX icon
27
Annexon
ANNX
$831M
$34.3M 0.96%
7,000,000
– –
RPTX
28
DELISTED
Repare Therapeutics
RPTX
$34.1M 0.96%
10,333,600
– –
FHTX icon
29
Foghorn Therapeutics
FHTX
$264M
$30.5M 0.85%
+5,302,000
New +$31.6M
CALT
30
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$29.2M 0.82%
750,000
– –
NAMS icon
31
NewAmsterdam Pharma
NAMS
$3.23B
$29.2M 0.82%
1,521,948
– –
ROIV icon
32
Roivant Sciences
ROIV
$24.3B
$29M 0.81%
2,742,409
– –
ENGN icon
33
enGene Therapeutics
ENGN
$117M
$21.2M 0.59%
2,251,037
– –
JANX icon
34
Janux Therapeutics
JANX
$923M
$18.5M 0.52%
441,528
-2,478,290
-85% -$116M
TCRX icon
35
TScan Therapeutics
TCRX
$48.6M
$17.5M 0.49%
2,989,474
– –
ELDN icon
36
Eledon Pharmaceuticals
ELDN
$259M
$16.6M 0.47%
6,293,282
+1,966,572
+45% +$4.69M
ALLK
37
DELISTED
Allakos
ALLK
$16.6M 0.46%
16,552,417
– –
IMUX icon
38
Immunic
IMUX
$189M
$9.88M 0.28%
890,297
– –
IMA
39
ImageneBio Inc
IMA
$62.9M
$7.87M 0.22%
397,430
– –
VIGL
40
DELISTED
Vigil Neuroscience
VIGL
$7.25M 0.2%
1,813,633
– –
VTGN icon
41
VistaGen Therapeutics
VTGN
$10M
$6.96M 0.2%
2,000,000
– –
CTMX icon
42
CytomX Therapeutics
CTMX
$686M
$6.38M 0.18%
5,228,461
-1,367,340
-21% -$2.72M
ELEV
43
DELISTED
Elevation Oncology
ELEV
$6.24M 0.18%
2,312,200
– –
VSTM icon
44
Verastem
VSTM
$490M
$5.02M 0.14%
1,685,219
– –
CDTX
45
DELISTED
Cidara Therapeutics
CDTX
$4.1M 0.11%
343,055
-1
-0% -$14
VERV
46
DELISTED
Verve Therapeutics
VERV
$3.17M 0.09%
650,000
– –
MOLN
47
Molecular Partners
MOLN
$3.17M 0.09%
443,221
– –
OVID icon
48
Ovid Therapeutics
OVID
$420M
$2.96M 0.08%
3,853,818
– –
SABS icon
49
SAB Biotherapeutics
SABS
$267M
$2.85M 0.08%
917,826
– –
CBIO
50
Crescent Biopharma
CBIO
$518M
$2.69M 0.08%
95,443
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2024 Portfolio in Review

As of Q2 2024, BVF Inc held 66 positions worth $3.57B, down 1.9% from $3.64B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

BVF Inc deployed $212M of net new capital in Q2 2024, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Axsome Therapeutics: 955,000 shares worth $76.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $116M trimmed.

  • BVF Inc's largest Q2 2024 buy was Axsome Therapeutics: 955,000 shares worth $76.9M.
  • BVF Inc added most to Structure Therapeutics in Q2 2024, an estimated $68.8M increase.
  • BVF Inc's biggest Q2 2024 reduction was Janux Therapeutics, cutting an estimated $116M.
  • BVF Inc fully exited Syndax Pharmaceuticals in Q2 2024, selling an estimated $44.6M.
  • BVF Inc's ten largest holdings make up 61% of its $3.57B portfolio in Q2 2024.
  • BVF Inc opened 4 new positions and closed 6 in Q2 2024.
  • BVF Inc's portfolio value fell 1.9% quarter-over-quarter to $3.57B.

Based on BVF Inc's 13F filing for Q2 2024, filed 14 Aug 2024.